Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel + Atezolizumab + Herceptin SC + Pertuzumab (TAHP) in HER2-positive Early Breast Cancer with Atezolizumab + Herceptin SC + Pertuzumab (AHP) Adjuvant Therapy
KCT0003774Phase 2Completed
- Sponsor
- Sanofi
- Start
- May 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel, atezolizumab, trastuzumab, pertuzumab in breast cancer, sponsored by Sanofi. Started May 2019; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on KCT0003774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003774.